DHX30

DHX30 is a DExH-box ATP-dependent RNA helicase that operates through two functionally distinct isoforms—a mitochondrial isoform that is a core component of mitochondrial RNA granules essential for mitoribosome biogenesis and mitochondrial translation, and a cytoplasmic isoform that represses translation of specific mRNAs and modulates stress granule assembly (PMID:25683715, PMID:34503222). The cytoplasmic isoform partners with PCBP2 to bind CG-rich motifs in 3′ UTRs of pro-apoptotic mRNAs, repressing their translation and thereby steering the p53-dependent cellular response toward arrest rather than apoptosis (PMID:32234473). DHX30 also functions as an intrinsic antiviral factor that binds viral RNA and inhibits viral replication in a helicase-activity-dependent manner, as demonstrated for both HIV-1 packaging and Seneca Valley virus replication (PMID:36000840, PMID:21204022). De novo missense mutations in conserved helicase-core motifs cause a neurodevelopmental disorder through a gain-of-function mechanism that promotes aberrant stress granule formation and global translation inhibition, while haploinsufficiency produces a milder phenotype (PMID:29100085, PMID:34020708).

1. 2006 High

   Identification of a mitochondrial isoform of DHX30 as a component of mtDNA nucleoids established the protein's dual compartmentalization and pointed to a mitochondrial function beyond its predicted RNA helicase activity.

   Evidence Subcellular fractionation and immunoaffinity purification of mtDNA nucleoids with isoform-specific antibodies in human cells

   PMID:16825194

   Open questions at the time

   • The RNA substrates of mitochondrial DHX30 were unknown
   • Whether the mitochondrial isoform had helicase activity on mitochondrial transcripts was untested
2. 2007 Medium

   DHX30 overexpression was shown to impair HIV-1 RNA packaging into virions despite enhancing gene expression, providing the first evidence that DHX30 could function as a host antiviral factor.

   Evidence Overexpression in cell culture with viral RNA quantification and infectivity assays

   PMID:18022663

   Open questions at the time

   • Mechanism of RNA packaging inhibition was unclear
   • Loss-of-function data were not provided
   • Effect was shown only for HIV-1
3. 2010 Medium

   Discovery of the physical interaction between DHX30 and the zinc-finger antiviral protein ZAP, and the requirement of DHX30 for optimal ZAP-mediated viral restriction, positioned DHX30 as a cofactor in innate antiviral defense.

   Evidence Pull-down, co-immunoprecipitation, and shRNA knockdown with viral replication readout

   PMID:21204022

   Open questions at the time

   • Whether DHX30 helicase activity was required for ZAP cooperation was untested
   • Generalizability to viruses beyond the ZAP-sensitive reporters was unknown
4. 2014 Medium

   Demonstration of in vitro helicase activity and embryonic lethality upon homozygous loss in mice established DHX30 as an essential developmental factor and confirmed its catalytic activity on nucleic acid substrates.

   Evidence Gene trap mutagenesis in mice, embryological analysis, and in vitro helicase untwisting assay with purified protein

   PMID:25219788

   Open questions at the time

   • Whether lethality arose from mitochondrial or cytoplasmic isoform loss was unknown
   • In vivo RNA substrates were uncharacterized
5. 2015 High

   Proteomic and functional studies demonstrated that DHX30 is a bona fide component of mitochondrial RNA granules required for mitoribosome assembly, defining its mitochondrial function at the process level.

   Evidence Proteomics of mitochondrial RNA granules, siRNA knockdown, and mitoribosome biogenesis assays

   PMID:25683715

   Open questions at the time

   • The specific step in mitoribosome biogenesis requiring DHX30 helicase activity was undefined
   • Whether DHX30 directly remodels mt-rRNAs or acts as a scaffold was unknown
6. 2017 High

   Patient-derived de novo missense mutations in conserved helicase-core motifs were shown to impair ATPase activity, increase stress granule formation, and inhibit global translation, establishing both the molecular basis of a neurodevelopmental disorder and DHX30's role in translational regulation.

   Evidence In vitro ATPase and RNA-binding assays, stress granule formation assays, polysome profiling across 12 individuals and 6 mutations

   PMID:29100085

   Open questions at the time

   • Whether stress granule induction was a gain-of-function or loss-of-function effect was debated
   • Specific mRNA targets affected in disease were unknown
7. 2020 High

   Identification of the DHX30–PCBP2 complex binding CG-rich 3′ UTR motifs (CGPD-motifs) on pro-apoptotic mRNAs revealed the mechanism by which cytoplasmic DHX30 steers p53-dependent responses toward cell cycle arrest rather than apoptosis.

   Evidence Polysome profiling, RNA immunoprecipitation, siRNA knockdown, inducible overexpression, and apoptosis assays

   PMID:32234473

   Open questions at the time

   • Whether PCBP2 recruits DHX30 or vice versa was unresolved
   • The structural basis for CGPD-motif recognition was unknown
8. 2021 High

   Systematic genotype–phenotype analysis across additional patients and animal models clarified that helicase-core-motif missense variants produce a detrimental gain-of-function in stress granule formation distinct from simple loss of helicase activity, while haploinsufficiency causes a milder phenotype—resolving the gain- versus loss-of-function debate.

   Evidence In vitro ATPase/helicase assays, CRISPR-knockout HEK293T cells, DHX30-deficient zebrafish behavioral analysis, global translation assays

   PMID:34020708

   Open questions at the time

   • The structural mechanism by which point mutations drive aberrant SG nucleation was undefined
   • Whether behavioral phenotypes in zebrafish map to the mitochondrial or cytoplasmic isoform was unknown
9. 2021 High

   Isoform-specific silencing and eCLIP mapping established that the cytoplasmic isoform is the principal modulator of global translation (including ribosomal protein mRNAs), while the mitochondrial isoform directly binds and promotes translation of nuclear-encoded mitoribosome transcripts, delineating isoform-specific functions.

   Evidence Isoform-specific siRNA, polysome profiling, eCLIP, RIP, mitochondrial OCR assays in multiple cell lines

   PMID:34503222

   Open questions at the time

   • The co-factors enabling isoform-specific RNA target selection were unidentified
   • How cytoplasmic DHX30 represses ribosomal protein mRNA translation mechanistically was unclear
10. 2022 High

    ALS-linked mutant FUS was shown to aberrantly interact with DHX30, inducing disulfide-mediated misfolding and cytoplasmic mislocalization that impairs mitochondrial translation and OXPHOS complex assembly, linking DHX30 dysfunction to ALS pathology.

    Evidence Co-immunoprecipitation, subcellular fractionation, blue-native PAGE, immunoelectron microscopy, and ALS-FUS patient spinal cord immunohistochemistry

    PMID:36163369

    Open questions at the time

    • Whether restoring DHX30 localization rescues mitochondrial defects in ALS-FUS models was untested
    • The specific disulfide bonds affected were not mapped
11. 2022 High

    DHX30 was established as a direct antiviral factor against Seneca Valley virus by binding viral 5′ UTR RNA and suppressing dsRNA production in a helicase-dependent manner; the virus counteracts DHX30 through 3Cpro-mediated cleavage, demonstrating a virus–host arms race.

    Evidence RIP-seq, co-IP, siRNA knockdown, overexpression, protease cleavage site mapping, dsRNA immunofluorescence

    PMID:36000840

    Open questions at the time

    • Generalizability of the dsRNA-suppression mechanism to other RNA viruses was untested
    • Whether DHX30 antiviral activity requires ZAP or operates independently was unresolved
12. 2024 Medium

    DHX30 was found to be recruited by lncRNA Anxa10-203 to stabilize Mc1r mRNA in trigeminal ganglion neurons, promoting neuronal excitability and orofacial neuropathic pain—extending DHX30's cytoplasmic function to mRNA stabilization beyond translational repression.

    Evidence RNA pull-down, RIP, FISH, shRNA knockdown, electrophysiology, mouse CCI-ION pain model

    PMID:38433184

    Open questions at the time

    • Whether DHX30 helicase activity is required for mRNA stabilization was untested
    • Mechanism by which DHX30 stabilizes rather than represses this particular mRNA was unexplained
    • Single-lab finding not yet independently replicated

• Key unresolved questions include the structural basis of isoform-specific RNA target selection, how helicase-core-motif mutations mechanistically nucleate aberrant stress granules, and whether the antiviral and translational-repression functions of cytoplasmic DHX30 operate through shared or independent RNA-binding mechanisms.
• No high-resolution structure of DHX30 bound to RNA substrates
• Relationship between SG-nucleation gain-of-function and CGPD-motif translational repression is undefined
• In vivo isoform-specific rescue experiments in mammalian disease models are lacking